Association of Triple Therapy with Improvement in Cholesterol Profiles over Two-Year Followup in the Treatment of Early Aggressive Rheumatoid Arthritis Trial

Arthritis and Rheumatology

Volumn 68, Issue 3, 2016, Pages 577-586

  Charles Schoeman, Christina ^a   Wang, Xiaoyan ^a   Lee, Yuen Yin ^a   Shahbazian, Ani ^a   Navarro Millán, Iris ^b   Yang, Shuo ^b   Chen, Lang ^b   Cofield, Stacey S ^b   Moreland, Larry W ^c   O'Dell, James ^d   Bathon, Joan M ^e   Paulus, Harold ^a   Bridges, S Louis ^b   Curtis, Jeffrey R ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

^d UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^e Columbia University ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CHOLESTEROL; ETANERCEPT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYCHLOROQUINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METHOTREXATE; PREDNISONE; SALAZOSULFAPYRIDINE; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ACTIVITY; DISEASE ACTIVITY SCORE; DISEASE SEVERITY; DRUG USE; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FOLLOW UP; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MIXED EFFECT LINEAR MODEL; MONOTHERAPY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHEUMATOID ARTHRITIS; STATISTICAL MODEL; TREATMENT OUTCOME; ARTHRITIS, RHEUMATOID; BLOOD; CLINICAL TRIAL; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; MIDDLE AGED; PATHOPHYSIOLOGY;

ARTHRITIS, RHEUMATOID; BLOOD SEDIMENTATION; C-REACTIVE PROTEIN; CHOLESTEROL; DRUG THERAPY, COMBINATION; ETANERCEPT; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIPOPROTEINS, HDL; LIPOPROTEINS, LDL; MALE; METHOTREXATE; MIDDLE AGED;

EID: 84963904734     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.39502     Document Type: Article

References (31)

1. Boers M, Dijkmans B, Gabriel S, Maradit-Kremers H, O'Dell J, Pincus T., Making an impact on mortality in rheumatoid arthritis: targeting cardiovascular comorbidity. Arthritis Rheum 2004; 50: 1734-9.
2. Van Doornum S, McColl G, Wicks IP., Accelerated atherosclerosis: an extraarticular feature of rheumatoid arthritis? [review]. Arthritis Rheum 2002; 46: 862-73.
3. Roman MJ, Moeller E, Davis A, Paget SA, Crow MK, Lockshin MD, et al., Preclinical carotid atherosclerosis in patients with rheumatoid arthritis. Ann Intern Med 2006; 144: 249-56.
4. Solomon DH, Karlson EW, Rimm EB, Cannuscio CC, Mandl LA, Manson JE, et al., Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation 2003; 107: 1303-7.
5. Maradit-Kremers H, Nicola PJ, Crowson CS, Ballman KV, Gabriel SE., Cardiovascular death in rheumatoid arthritis: a population-based study. Arthritis Rheum 2005; 52: 722-32.
6. Hudgins LC, Parker TS, Levine DM, Gordon BR, Saal SD, Jiang XC, et al., A single intravenous dose of endotoxin rapidly alters serum lipoproteins and lipid transfer proteins in normal volunteers. J Lipid Res 2003; 44: 1489-98.
7. Pollono EN, Lopez-Olivo MA, Lopez JA, Suarez-Almazor ME., A systematic review of the effect of TNF-α antagonists on lipid profiles in patients with rheumatoid arthritis. Clin Rheumatol 2010; 29: 947-55.
8. Dahlqvist SR, Engstrand S, Berglin E, Johnson O., Conversion towards an atherogenic lipid profile in rheumatoid arthritis patients during long-term infliximab therapy. Scand J Rheumatol 2006; 35: 107-11.
9. Robertson J, Peters MJ, McInnes IB, Sattar N., Changes in lipid levels with inflammation and therapy in RA: a maturing paradigm. Nat Rev Rheumatol 2013; 9: 513-23.
10. Kirkham BW, Wasko MC, Hsia EC, Fleischmann RM, Genovese MC, Matteson EL, et al., Effects of golimumab, an anti-tumour necrosis factor-α human monoclonal antibody, on lipids and markers of inflammation. Ann Rheum Dis 2014; 73: 161-9.
11. Moreland LW, O'Dell JR, Paulus HE, Curtis JR, Bathon JM, St.Clair EW, et al, for the TEAR Investigators. A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the Treatment of Early Aggressive Rheumatoid Arthritis trial. Arthritis Rheum 2012; 64: 2824-35.
12. Navarro-Millan I, Charles-Schoeman C, Yang S, Bathon JM, Bridges SL Jr, Chen L, et al., Changes in lipoproteins associated with methotrexate or combination therapy in early rheumatoid arthritis: results from the Treatment of Early Rheumatoid Arthritis trial. Arthritis Rheum 2013; 65: 1430-8.
13. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL., Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995; 38: 44-8.
14. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al., The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-24.
15. Friedewald WT, Levy RI, Fredrickson DS., Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502.
16. Laird NM, Ware JH., Random-effects models for longitudinal data. Biometrics 1982; 38: 963-74.
17. Boers M, Nurmohamed MT, Doelman CJ, Lard LR, Verhoeven AC, Voskuyl AE, et al., Influence of glucocorticoids and disease activity on total and high density lipoprotein cholesterol in patients with rheumatoid arthritis. Ann Rheum Dis 2003; 62: 842-5.
18. Jamnitski A, Visman IM, Peters MJ, Dijkmans BA, Voskuyl AE, Nurmohamed MT., Beneficial effect of 1-year etanercept treatment on the lipid profile in responding patients with rheumatoid arthritis: the ETRA study. Ann Rheum Dis 2010; 69: 1929-33.
19. Steiner G, Urowitz MB., Lipid profiles in patients with rheumatoid arthritis: mechanisms and the impact of treatment. Semin Arthritis Rheum 2009; 38: 372-81.
20. Charles-Schoeman C, Watanabe J, Lee YY, Furst DE, Amjadi S, Elashoff D, et al., Abnormal function of high-density lipoprotein is associated with poor disease control and an altered protein cargo in rheumatoid arthritis. Arthritis Rheum 2009; 60: 2870-9.
21. Charles-Schoeman C, Lee YY, Shahbazian A, Gorn AH, FitzGerald J, Ranganath VK, et al., Association of paraoxonase 1 gene polymorphism and enzyme activity with carotid plaque in rheumatoid arthritis. Arthritis Rheum 2013; 65: 2765-72.
22. Souto A, Salgado E, Maneiro JR, Mera A, Carmona L, Gomez-Reino JJ., Lipid profile changes in patients with chronic inflammatory arthritis treated with biologic agents and tofacitinib in randomized clinical trials: a systematic review and meta-analysis. Arthritis Rheumatol 2015; 67: 117-27.
23. Morris SJ, Wasko MC, Antohe JL, Sartorius JA, Kirchner HL, Dancea S, et al., Hydroxychloroquine use associated with improvement in lipid profiles in rheumatoid arthritis patients. Arthritis Care Res (Hoboken) 2011; 63: 530-4.
24. Kerr G, Aujero M, Richards J, Sayles H, Davis L, Cannon G, et al., Associations of hydroxychloroquine use with lipid profiles in rheumatoid arthritis: pharmacologic implications. Arthritis Care Res (Hoboken) 2014; 66: 1619-26.
25. Munro R, Morrison E, McDonald AG, Hunter JA, Madhok R, Capell HA., Effect of disease modifying agents on the lipid profiles of patients with rheumatoid arthritis. Ann Rheum Dis 1997; 56: 374-7.
26. Beynen AC, van der Molen AJ, Geelen MJ., Inhibition of hepatic cholesterol biosynthesis by chloroquine. Lipids 1981; 16: 472-4.
27. Garrison RJ, Wilson PW, Castelli WP, Feinleib M, Kannel WB, McNamara PM., Obesity and lipoprotein cholesterol in the Framingham offspring study. Metabolism 1980; 29: 1053-60.
28. Wilson PW, Garrison RJ, Abbott RD, Castelli WP., Factors associated with lipoprotein cholesterol levels: the Framingham Study. Arteriosclerosis 1983; 3: 273-81.
29. Matthews KA, Meilahn E, Kuller LH, Kelsey SF, Caggiula AW, Wing RR., Menopause and risk factors for coronary heart disease. N Engl J Med 1989; 321: 641-6.
30. Sidhu D, Naugler C., Fasting time and lipid levels in a community-based population: a cross-sectional study. Arch Intern Med 2012; 172: 1707-10.
31. Eberly LE, Stamler J, Neaton JD., Relation of triglyceride levels, fasting and nonfasting, to fatal and nonfatal coronary heart disease. Arch Intern Med 2003; 163: 1077-83.